Shares of AbbVie Inc. ABBV rose 1.79% to $200.88 Thursday, on what proved to be an all-around poor trading session for the ...

Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Dividend-growth stocks offer steady income and long-term value. With the Fed holding rates and inflation expected to ease, ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global ...

AbbVie just rewarded its shareholders again with a dividend. This stock has boosted its payout annually for more than 50 ...

Shares in biotech group Xilio Therapeutics (XLO) surged over 125% today after it sealed a cancer-fighting deal with AbbVie ...

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying AbbVie Inc. (NYSE:ABBV), saying it's “just a gem” and a “winner.”  He added, “I can't believe the stock dropped so much.” ...